AMSTERDAM — Corbion announced its collaboration with BRAIN Biotech AG to develop novel bio-based antimicrobial compounds and derivatives.
“At Corbion, advancing the state of the art in nature-based ingredient technologies, proving and expanding on their value and efficacy, is essential to preserving what matters,” said Domenico Vulcano, VP of global innovation at Corbion. “One of the ways we continue to strengthen our investment in innovation is through establishing partnerships with other experts like those at BRAIN Biotech. We believe this kind of collaboration will help us bring the next paradigm-changing breakthroughs to market sooner.”